William Blair Brokers Reduce Earnings Estimates for RARE

Key Points

• William Blair analysts have revised their Q3 2025 earnings per share estimate for Ultragenyx Pharmaceutical from ($1.32) to (1.34), maintaining an "Outperform" rating with a $65.00 price target.
• Ultragenyx reported Q2 earnings of ($1.17) per share, exceeding expectations of ($1.27), with revenues of $166.50 million, up 13.2% year-over-year.
• The stock has a consensus rating of "Moderate Buy" with a target price of $82.17, while institutional investors own 97.67% of the shares currently.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Analysts at William Blair dropped their Q3 2025 EPS estimates for Ultragenyx Pharmaceutical in a research report issued on Tuesday, August 5th. William Blair analyst S. Corwin now expects that the biopharmaceutical company will post earnings of ($1.34) per share for the quarter, down from their previous forecast of ($1.32). William Blair currently has a "Outperform" rating and a $65.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. William Blair also issued estimates for Ultragenyx Pharmaceutical's Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($5.31) EPS, Q1 2026 earnings at ($1.39) EPS, Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at $0.42 EPS and FY2026 earnings at ($1.06) EPS.

RARE has been the subject of several other research reports. Cantor Fitzgerald dropped their price target on shares of Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating for the company in a research report on Wednesday, August 6th. HC Wainwright raised shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price objective for the company in a research report on Monday, July 28th. Wedbush dropped their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research report on Monday, July 14th. Canaccord Genuity Group dropped their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research report on Friday. Finally, Morgan Stanley decreased their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $81.50.

Ultragenyx Pharmaceutical Price Performance

RARE stock traded up $0.39 on Friday, hitting $27.78. 550,629 shares of the company were exchanged, compared to its average volume of 1,291,107. Ultragenyx Pharmaceutical has a twelve month low of $25.81 and a twelve month high of $60.37. The business's fifty day moving average is $33.15 and its two-hundred day moving average is $36.56. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of -5.02 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. The company had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm's quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.52) earnings per share.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director directly owned 15,344 shares in the company, valued at $573,712.16. This represents a 13.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD lifted its position in shares of Ultragenyx Pharmaceutical by 28.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock worth $116,559,000 after buying an additional 706,519 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in shares of Ultragenyx Pharmaceutical by 81.6% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock worth $77,815,000 after buying an additional 965,919 shares during the last quarter. Federated Hermes Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 0.3% in the 1st quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company's stock worth $74,419,000 after buying an additional 5,400 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 4.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company's stock worth $62,291,000 after buying an additional 66,394 shares during the last quarter. Finally, Deutsche Bank AG lifted its position in shares of Ultragenyx Pharmaceutical by 0.5% in the 1st quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company's stock worth $61,611,000 after buying an additional 8,385 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.